Business Wire

Carta Launches Unified Fund of Funds Solution to Automate LP Workflows and Portfolio Visibility

24.3.2026 12:01:00 EET | Business Wire | Press release

Share

Carta, the world’s first fully interconnected system for private capital, today announced its solution for Fund of Funds, a new offering designed to help managers automate LP reporting, eliminate manual document processing, and gain clearer visibility into their underlying portfolio exposure. The product expands a critical link in Carta’s ERP for private capital, bringing LP investment data, fund accounting, and portfolio analytics onto a single platform, while more deeply connecting allocators with the GP ecosystem.

Fund of Funds represents a critical and growing segment of the private capital ecosystem, projected to reach $450 billion by 2033 as investors seek diversified exposure to private markets. Yet, operating a fund of funds remains highly complex. Managers sit at a unique intersection of the ecosystem, investing as LPs across multiple funds while also serving as GPs to their own investors. As a result, teams are forced to navigate dozens or more of LP portals, manually process investment documents, and reconcile data across multiple investment layers. These fragmented workflows slow reporting cycles and obscure visibility into underlying portfolio exposure.

“Fund of Funds managers have been stuck in a perpetual data chase, juggling dozens of portals, manually re-keying data from PCAPs into spreadsheets, and watching their reporting lag weeks behind the rest of the market,” said Vrushali Paunikar, Chief Product Officer, Carta. “We’re ending that. Our platform unifies fund administration, portfolio analytics, and document automation in one place, and our agentic AI powers the flow-through accounting that makes it all work, even for funds not administered on Carta. This is the missing piece of the private capital ERP.”

Streamlining Complexity: Carta’s Solution for Fund of Funds

Carta’s solution for Fund of Funds addresses modern operational challenges by consolidating fund administration, portfolio analytics, and document management into a single system. Critically, the platform aggregates all data across a manager’s entire portfolio, including funds that are not administered on Carta. Further, by unifying the GP and LP experience on a single platform, Carta is advancing its vision of a Network ERP for Private Capital, one connected system for every stakeholder across the private markets ecosystem.

  • Proprietary Agentic AI for Seamless Data Flow and Accounting Automation: The platform deploys proprietary agentic AI to ingest, extract and normalize data from key statements such as capital call notices and PCAPs. This transforms static, unstructured documents into a live data feed that automatically updates the general ledger, eliminating manual entry and streamlining close and reporting cycles. One of the most significant operational bottlenecks for a Fund of Funds is the ingestion of quarterly financials. In Carta’s case, LLMs break through that bottleneck with near real-time updates to accounting workbooks.
  • Deep Portfolio Look-Through Analysis: Investment teams can analyze portfolio exposure and ownership data within a single interface instead of manually aggregating information from GP reports. Managers can understand their exact exposure to underlying portfolio companies across multiple funds simultaneously while also managing compliance per the 5% GAAP disclosure rule. They can also perform side-by-side comparisons of how different GPs value the same underlying company to understand valuation deltas.
  • Centralized Capital Activity Hub: All capital activity notices, capital calls, distributions, and transfers are tracked and actionable from a single hub, replacing the fragmented experience of managing dozens of LP portals and browser tabs.
  • Comprehensive Visual Accounting: The platform maps complex entity relationships, fund accounting, and performance data across the entirety of a portfolio. This allows users to trace capital flows with powerful visual accounting capabilities from an investment vehicle down to an individual asset with deal-level detail.

Looking Ahead

The launch of the Fund of Funds solution is the first step in a broader roadmap for accounting automation. In the coming months, Carta will introduce directional cash forecasting and integrated treasury management tools to help managers handle liquidity across their entire network—equipping Fund of Funds managers to operate as the liquidity innovators the market increasingly demands.

Carta’s solution for Fund of Funds is available now. To learn more, visit: http://carta.com/solutions/fund-of-funds/

To learn more about Carta, follow us on LinkedIn, X, Instagram, YouTube, or visit carta.com.

About Carta

Carta is the ERP for private capital, connecting the entire ecosystem—from GPs and LPs to CEOs, CFOs, employees, and advisors. Trusted by 50,000 companies in 160+ countries, our platform streamlines every ownership workflow, making it easier to understand, manage, and grow equity. With software and services built to scale, Carta empowers you to build, invest, and grow with confidence. Carta’s Fund Administration platform supports 9,000 funds and SPVs, representing $203B+ in assets under management, with tools designed to enhance the strategic impact of Fund CFOs. Recognized by Fortune, Forbes, Fast Company, Inc. and Great Places to Work, Carta is transforming how private capital operates.

For more information visit carta.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20260324569161/en/

Contacts

Media Contact:
Madeline Perry, Communications Coordinator
press@carta.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye